Home > News > HemoBioTech Chief Executive Officer Provides Year End Review
December 28th, 2006
HemoBioTech Chief Executive Officer Provides Year End Review
Abstract:
Our recent participation in the NanoTech 2006 conference in Dallas introduced us to several European companies that assist in clinical research, and we have initiated preliminary discussions. We believe HemoTech(TM) has worldwide applications and we intend to address these foreign markets.
Source:
yahoo.com
Bookmark:
| Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Announcements
Enhancing power factor of p- and n-type single-walled carbon nanotubes April 25th, 2025
Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs April 25th, 2025
Ultrafast plasmon-enhanced magnetic bit switching at the nanoscale April 25th, 2025
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Human Interest/Art
New 2D multifractal tools delve into Pollock's expressionism January 17th, 2025
Drawing data in nanometer scale September 30th, 2022
Scientists prepare for the world’s smallest race: Nanocar Race II March 18th, 2022
Graphene nanotubes revolutionize touch screen use for prosthetic hands August 3rd, 2021
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||